A groundbreaking collaborative approach to

Clinical Trials.

Introducing the Lung Cancer Master Protocol (Lung-MAP), a first-of-its-kind clinical trial that uses a multi-drug, targeted screening method to match patients with studies of investigational new treatments.

I am a patientI am a healthcare provider/researcher

How it works.

Genomic profile screening

Patients are screened using a comprehensive genomic profiling platform that looks at over 200 cancer-related genes for genomic alterations.Learn more

Sub-study assignment

Based on the results of this screening, patients are assigned to whichever one of up to five sub-studies testing different investigational treatment regimens best suits their genomic profile.Learn more

Innovative approach

This innovative approach improves a patient's likelihood of receiving a drug targeted at the genetic profile of their particular tumor while allowing for new therapies in development to be added as the trial progresses.Learn more

Find a cancer center

The trial is open at a nework of cancer centers, community hospitals, academic medical centers, and physican cooperatives across the United States with operations being managed by SWOG Cancer Research within the National Cancer Institute's National Clinical Trials Network.